Moolec Science SA
MLEC Healthcare Biotechnology
In the quarter to December 2025, revenue grew 948.4%, EPS fell 20.0% and free cash flow grew 4.48%, each against the same quarter a year earlier.
Follow MLEC
Moolec Science SA (MLEC) EV/Sales
As of 16 October 2026, Moolec Science SA (MLEC) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from 0.0× (March 2024) to 20.5× (April 2024); the current reading is higher than 77% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.1× | (90.10%) |
| FY2024 | 1.0× | — |
| FY2023 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 0.1× | (2.67%) |
| Sep 2024 | 0.1× | (88.31%) |
| Jun 2024 | 1.0× | (92.00%) |
| Mar 2024 | 12.0× | — |
| 3 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CARM Carisma Therapeutics Inc. compare | 0.0× |
| NEXI NexImmune, Inc. compare | n/m |
| PTIX Atrinsic Inc. compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| CYTOF Altamira Therapeutics Ltd. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| ABPO Abpro Holdings Inc. compare | n/m |
| MLEC Moolec Science SA | 0.1× |
| ITRMF Iterum Therapeutics PLC compare | 24.4× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)